文献速递细菌感染、耐药与抗菌药物医院感染防控

多重耐药革兰阴性菌和耐万古霉素肠球菌携带者感染发生率:系统综述与荟萃回归分析

Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis.
PubMed 文献 · Lancet Infect Dis · 2023-01-30

该系统综述与荟萃回归分析检索1995年至2022年随访研究,纳入44项研究、14049例多重耐药菌定植患者,评估肠道定植后感染风险。结果显示30天时多重耐药革兰阴性菌定植者合并感染累积发生率为14%(95%CI 10-18),耐万古霉素肠球菌定植者为8%(5-13),碳青霉烯耐药革兰阴性菌定植者最高(19%,95%CI 15-25)。

要点

  • 30天时多重耐药革兰阴性菌定植者感染累积发生率为14%(95%CI 10-18)。
  • 30天时耐万古霉素肠球菌定植者感染累积发生率为8%(95%CI 5-13)。
  • 碳青霉烯耐药革兰阴性菌定植者30天感染累积发生率最高,为19%(95%CI 15-25)。

核心结论

  • 定植者感染风险较高,碳青霉烯耐药革兰阴性菌定植者风险最高,耐万古霉素肠球菌定植者最低。
  • 这些数据可能有助于指导预防和治疗决策,并为靶向预防临床试验的设计提供宝贵资源。

研究设计与样本

  • 系统综述与荟萃回归分析,检索PubMed、Embase、Web of Science核心合集和Google Scholar。
  • 纳入1995年1月1日至2022年3月17日发表的随访研究,测量多重耐药革兰阴性菌感染发生率;以及1995年1月1日至2022年3月15日发表的随访研究,测量耐万古霉素肠球菌感染发生率。
  • 纳入原始队列研究和病例对照研究,要求采用发病密度抽样,纳入50例及以上肠道定植或尿样本阳性作为定植替代标志物的患者,或两者兼有,并分析明确先于定植的感染。
  • 未使用语言限制;排除未报告随访时长的研究。
  • 最终纳入来自14个国家的44项研究(26项关于多重耐药革兰阴性菌,14项关于耐万古霉素肠球菌,4项同时涉及两者),其中40项进行荟萃回归分析,包含14049例多重耐药菌定植患者的数据。

主要发现

  • 多重耐药革兰阴性菌定植者30天中位随访时合并感染累积发生率为14%(95%CI 10-18;p<0.0001),9034例定植患者中845例感染。
  • 耐万古霉素肠球菌定植者30天合并感染累积发生率为8%(95%CI 5-13;p<0.0001),4747例定植患者中229例感染。
  • 碳青霉烯耐药革兰阴性菌定植者30天感染发病密度为每1000患者日4.26例感染(95%CI 1.69-6.82),累积发生率为19%(95%CI 15-25;p<0.0001),4547例定植患者中602例感染。
  • 偏倚风险评为低至中等。

关键数值与推荐

  • 定植定义为粪便或尿液培养检出多重耐药革兰阴性菌或耐万古霉素肠球菌。
  • 主要结局为定植患者感染的累积发生率和发病密度。
  • 采用广义线性混合效应荟萃回归估计合并发生率,并校正随访时长差异。
  • 研究注册号PROSPERO CRD42020222415。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carriers of multidrug-resistant bacteria are at risk of infections with these bacteria; the precise size of this risk is unclear. We aimed to quantify the effect of gut colonisation on subsequent risk of infection with multidrug-resistant bacteria. METHODS: We performed a systematic review and meta-regression analysis. We searched PubMed, Embase, Web of Science Core Collection, and Google Scholar for follow-up studies published from Jan 1, 1995, to March 17, 2022, that measured the incidence of infections with multidrug-resistant Gram-negative bacteria (MDR-GNB) and from Jan 1, 1995, to March 15, 2022, that measured the incidence of infections with vancomycin-resistant enterococci (VRE). We included original cohort studies and case-control studies that used incidence-density sampling, included 50 or more patients with enteric colonisation or positive urinary samples as a surrogate marker of colonisation, or both, and analysed infections clearly preceded by colonisation. We did not use any language restrictions. We excluded studies not reporting length of follow-up. Summary data were extracted and independently cross-verified by two authors. Carriage was defined as MDR-GNB or VRE, detected in faecal or urinary cultures. Our primary outcomes were cumulative incidence and incidence density of infection in patients colonised by multidrug-resistant bacteria. To estimate pooled incidences, general linearised mixed-effects meta-regressions were used, adjusting for varying follow-up durations. This study is registered with PROSPERO, CRD42020222415. FINDINGS: Of the 301 studies identified, 44 studies (26 on MDR-GNB, 14 on VRE, and four on both MDR-GNB and VRE) from 14 countries were retained for qualitative synthesis, 40 of which were analysed with meta-regression, comprising data for 14 049 patients colonised with multidrug-resistant bacteria. The pooled cumulative incidence of infection was 14% (95% CI 10-18; p<0·0001) at a median follow-up time of 30 days for MDR-GNB (845 cases of infection in 9034 patients colonised) and 8% (5-13; p<0·0001) at 30 days for VRE (229 cases of infection in 4747 patients colonised). Infection incidence density (4·26 infections per 1000 patient-days; 95% CI 1·69-6·82) and cumulative incidence of infection (19%, 95% CI 15-25; p<0·0001; 602 cases of infection in 4547 patients colonised) were highest for carbapenem-resistant Gram-negative bacteria at 30 days. Risk of bias was rated low to moderate. INTERPRETATION: The risk of infection was substantial, with the highest risk for patients colonised with carbapenem-resistant Gram-negative bacteria and the lowest in patients with VRE. These data might help to guide prophylactic and treatment decisions and form a valuable resource for planning clinical trials on targeted prevention. FUNDING: The Netherlands Organization for Health Research and Development.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Willems RPJ, van Dijk K, Vehreschild MJGT, et al. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis. 2023. PMID: 36731484. doi:10.1016/S1473-3099(22)00811-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。